GT Biopharma, Inc. filed a Form 8-K on November 12, 2026, reporting the results of a Special Meeting of Stockholders held on November 11, 2026, at which four proposals were submitted to a vote.
Key Highlights
- Record date shares: As of September 30, 2026, there were 2,061,052 shares of common stock outstanding and entitled to vote.
- Quorum: A total of 1,146,416 shares, or approximately 55.62% of eligible shares, were present in person or by proxy, constituting a quorum.
- Obsolete Preferred Stock Elimination approved: The proposal received 1,062,602 votes for, 67,623 against, and 16,191 abstentions.
- Authorized share increase approved: The proposal to raise authorized common stock from 25,000,000 to 250,000,000 received 892,003 votes for, 223,266 against, and 31,147 abstentions.
- Issuance Proposal approved: The proposal permitting issuance of 19.99% or more of outstanding shares under a Securities Purchase Agreement dated September 14, 2026, received 485,607 votes for, 49,077 against, 9,592 abstentions, and 602,140 broker non-votes.
- Adjournment Proposal approved: The adjournment proposal received 502,185 votes for, 30,877 against, 11,214 abstentions, and 602,140 broker non-votes.
GT Biopharma Stockholders Approve Charter Amendments and Share Issuance at November 2026 Special Meeting
According to the filing, GT Biopharma, Inc. (NASDAQ:GTBP) held a Special Meeting of Stockholders on November 11, 2026. The company disclosed that, as of the September 30, 2026 record date, 2,061,052 shares of common stock, par value $0.001 per share, were outstanding and eligible to vote. Of those, 1,146,416 shares, or approximately 55.62%, were represented at the meeting, satisfying the quorum requirement.
Four proposals were considered. The first, described in the filing as the "Obsolete Preferred Stock Elimination Proposal," sought approval of an amendment and restatement of the Company's Restated Certificate of Incorporation to remove references to series of preferred stock that are "no longer designated, issued or outstanding," effective at any time on or prior to November 11, 2027. It was approved by a wide margin. The second proposal to increase authorized common stock from 25,000,000 to 250,000,000 shares, also effective on or prior to November 11, 2027, was approved to support general corporate purposes and potential share issuances related to the Series M 10% Convertible Preferred Stock and associated warrants.
The third proposal, the "Issuance Proposal," sought stockholder approval under Nasdaq Rule 5635 for the issuance of 19.99% or more of outstanding common stock in connection with a Securities Purchase Agreement dated September 14, 2026. This covered shares issuable upon conversion of Series M Preferred Stock and exercise of Common Stock Warrants and Vesting Warrants, as the filing defines those terms. The proposal was approved, though 602,140 broker non-votes were recorded. A fourth adjournment proposal, included as a contingency measure, was also approved. The filing was signed by Alan Urban, Chief Financial Officer, on November 12, 2026.
What Was Disclosed
GT Biopharma reported the voting results from its November 11, 2026 Special Meeting of Stockholders, covering four proposals: elimination of obsolete preferred stock references, an increase in authorized common shares, approval of a share issuance under a September 2026 securities agreement, and an adjournment provision. All four proposals were approved.




Please wait processing your request...